Evidence map›Paper›PMID 35296265›Full record

ArticleBMC infectious diseases2022

High seroprevalence of anti-SARS-CoV-2 antibodies among Ethiopian healthcare workers.

Tesfaye Gelanew, Berhanu Seyoum, Andargachew Mulu, Adane Mihret, Markos Abebe, Liya Wassie, Baye Gelaw, Abebe Sorsa, Yared Merid, Yilkal Muchie and 20 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors at 9 institutions in 4 countries.

Tesfaye GelanewArmauer Hansen Research Institute, Addis Ababa, Ethiopia. tesfaye.gelanew@ahri.gov.et.
Berhanu SeyoumArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Andargachew MuluArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Adane MihretArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Markos AbebeArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Liya WassieArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Baye GelawDepartment of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Abebe SorsaArsi University, Asella College of Health Sciences, Asella, Ethiopia.
Yared MeridCollege of Medicine and Health Sciences, Department of Medical Microbiology, Hawassa University, Hawassa, Ethiopia.
Yilkal MuchieArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Zelalem TeklemariamDepartment of Medical Laboratory Sciences College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.
Bezalem TesfayeArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Mahlet OsmanArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Gutema JebessaArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Abay AtinafuArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Tsegaye HailuArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Antenehe HabteArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Dagaga KeneaArsi University, Asella College of Health Sciences, Asella, Ethiopia.
Anteneh GadisaCollege of Medicine and Health Sciences, Department of Medical Microbiology, Hawassa University, Hawassa, Ethiopia.
Desalegn AdmasuDepartment of Medical Laboratory Sciences College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.
Emnet TesfayeCollege of Medicine and Health Sciences, Department of Medical Microbiology, Hawassa University, Hawassa, Ethiopia.
Timothy A BatesDepartment of Molecular Microbiology and Immunology, Oregon Health & Sciences University, Portland, OR, USA.
Jote Tafese BulchaHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, USA.
Rea TschoppArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Dareskedar TsehayArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Kim MullholandLondon School of Hygiene and Tropical Medicine, London, UK.
Rawleigh HoweArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Abebe GenetuArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Fikadu G Tafesse *Department of Molecular Microbiology and Immunology, Oregon Health & Sciences University, Portland, OR, USA. tafesse@ohsu.edu.
Alemseged Abdissa *Armauer Hansen Research Institute, Addis Ababa, Ethiopia. alemseged.abdissa@ahri.gov.et.
Armauer Hansen Research Institute · ETHawassa University · ETHaramaya University · ETOregon Health & Science University · USArsi UniversityAsossa University · ETLondon School of Hygiene & Tropical Medicine · GBUniversity of Gondar · ETUniversity of Massachusetts Chan Medical School · US

Funding

Multidisciplinary Research Training in Pulmonary MedicineT32HL083808 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI LEWINSOHN, DAVID M., SLATORE, CHRISTOPHER G. · 2008 to 2025
$5.3M
Ethiopia-Emory TB Research Training ProgramD43TW009127 · FIC · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Kidist Bobosha · 2013 to 2026
$3.4M
NHLBI NIH HHS T32 HL083808
6 · The paper itself

Abstract

backgroundCOVID-19 pandemic has a devastating impact on the economies and health care system of sub-Saharan Africa. Healthcare workers (HWs), the main actors of the health system, are at higher risk because of their occupation. Serology-based estimates of SARS-CoV-2 infection among HWs represent a measure of HWs' exposure to the virus and could be used as a guide to the prevalence of SARS-CoV-2 in the community and valuable in combating COVID-19. This information is currently lacking in Ethiopia and other African countries. This study aimed to develop an in-house antibody testing assay, assess the prevalence of SARS-CoV-2 antibodies among Ethiopian high-risk frontline HWs.

methodsWe developed and validated an in-house Enzyme-Linked Immunosorbent Assay (ELISA) for specific detection of anti-SARS-CoV-2 receptor binding domain immunoglobin G (IgG) antibodies. We then used this assay to assess the seroprevalence among HWs in five public hospitals located in different geographic regions of Ethiopia. From consenting HWs, blood samples were collected between December 2020 and February 2021, the period between the two peaks of COVID-19 in Ethiopia. Socio-demographic and clinical data were collected using questionnaire-based interviews. Descriptive statistics and bivariate and multivariate logistic regression were used to determine the overall and post-stratified seroprevalence and the association between seropositivity and potential risk factors.

resultsOur successfully developed in-house assay sensitivity was 100% in serum samples collected 2- weeks after the first onset of symptoms whereas its specificity in pre-COVID-19 pandemic sera was 97.7%. Using this assay, we analyzed a total of 1997 sera collected from HWs. Of 1997 HWs who provided a blood sample, and demographic and clinical data, 51.7% were females, 74.0% had no symptoms compatible with COVID-19, and 29.0% had a history of contact with suspected or confirmed patients with SARS-CoV-2 infection. The overall seroprevalence was 39.6%. The lowest (24.5%) and the highest (48.0%) seroprevalence rates were found in Hiwot Fana Specialized Hospital in Harar and ALERT Hospital in Addis Ababa, respectively. Of the 821 seropositive HWs, 224(27.3%) of them had a history of symptoms consistent with COVID-19 while 436 (> 53%) of them had no contact with COVID-19 cases as well as no history of COVID-19 like symptoms. A history of close contact with suspected/confirmed COVID-19 cases is associated with seropositivity (Adjusted Odds Ratio (AOR) = 1.4, 95% CI 1.1-1.8; p = 0.015).

conclusionHigh SARS-CoV-2 seroprevalence levels were observed in the five Ethiopian hospitals. These findings highlight the significant burden of asymptomatic infection in Ethiopia and may reflect the scale of transmission in the general population.

Indexed as

COVID-19PandemicsEthiopiaFemaleHealth PersonnelHumansSARS-CoV-2Seroepidemiologic StudiesAntibodiesCOVID-19ELISAEthiopiaRBDSARS-CoV-2Seroprevalence

Identifiers

PMID35296265
PMCPMC8926102
OpenAlexW4225644307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.